Solid lipid nanoparticles comprising internal Compritol 888 ATO, tripalmitin and cacao butter for encapsulating and releasing stavudine, delavirdine and saquinavir

Solid lipid nanoparticles (SLNs) with complex internal phase were fabricated for formulating stavudine (D4T), delavirdine (DLV), and saquinavir (SQV). The lipids including Compritol 888 ATO, tripalmitin, and cacao butter were stabilized by L-α-phospatidylcholine, cholesteryl hemisuccinate, and taurocholate to form SLNs. The results revealed that the morphology of SLNs was spheroidal with shallow surface pits. An increase in the weight percentage of Compritol 888 ATO increased the average diameter of D4T-entrapping SLNs and decreased that of DLV- and SQV-entrapping SLNs. Preservation at 4°C over 6 weeks slightly enhanced the size of SLNs. For a specific drug, an increase in the entrapment efficiency enlarged the nanocarriers. The order of drug in the average particle diameter and in the entrapment efficiency was SQV>DLV>D4T, in general. In addition, the dissolution of the three drugs from SLNs showed the characteristics of sustained release. The order of drug in the cumulative release percentage was D4T>DLV>SQV. SLNs containing Compritol 888 ATO, tripalmitin, and cacao butter are efficient in carrying antiretroviral agents for medicinal application.     

Polyethyleneimine/poly-(γ-glutamic acid)/poly(lactide-co-glycolide) nanoparticles for loading and releasing antiretroviral drug

Nanoparticles (NPs) with ternary components of polyethyleneimine (PEI), poly-(γ-glutamic acid) (γ-PGA), and poly(lactide-co-glycolide) (PLGA) were applied to carry and release saquinavir (SQV). Hydrophobic SQV was encapsulated in the particle core composed of PLGA to form SQV-PLGA NPs, and the surface of SQV-PLGA NPs was grafted successively with hydrophilic γ-PGA and PEI (PEI/γ-PGA/SQV-PLGA NPs). The morphological images revealed that PEI/γ-PGA/SQV-PLGA NPs were spheroid-like, in general. An increase in the concentration of didecyl dimethylammonium bromide and a reduction in the dose of SQV enhanced the entrapment efficiency of SQV in PLGA NPs. In addition, an increment in the molecular weight of γ-PGA reduced the grafting efficiency of PEI on γ-PGA/SQV-PLGA NPs. An increase in the weight percentage of PEI enhanced the average particle diameter. However, the grafting efficiency of PEI on γ-PGA/SQV-PLGA NPs and the dissolution rate of SQV from PEI/γ-PGA/SQV-PLGA NPs reduced when the weight percentage of PEI increased. PEI/γ-PGA/SQV-PLGA NPs are an innovative drug delivery system and can be used for antiretroviral trials.     

Expression of ornithine decarboxylase during the transport of saquinavir across the blood-brain barrier using composite polymeric nanocarriers under an electromagnetic field

The expression of human ornithine decarboxylase (ODC) and permeability of saquinavir (SQV) across the blood-brain barrier were studied using nanoparticles (NPs) composed of poly(lactide-co-glycolide) (PLGA), poly-(γ-glutamic acid) (γ-PGA), and polyethyleneimine (PEI). SQV was encapsulated in the particle core to traverse a monolayer of human brain-microvascular endothelial cells (HBMECs) with the regulation of human astrocytes under an electromagnetic field (EMF). An increase in the weight percentage of PEI enhanced the particle size, zeta potential, and permeability of SQV. However, the viability of HBMECs reduced when the weight percentage of PEI increased. In addition, an increment in the molecular weight of γ-PGA enhanced the particle size and viability of HBMECs, and reduced the zeta potential. The permeability of SQV and expression of ODC were in the order: an EMF with amplitude modulation (AM)>an EMF with frequency modulation>no EMF. At 0.04% PEI, the AM EMF increased 2.38 times the uptake of NPs and 2.72 times the expression of ODC. The combination of PEI/γ-PGA/PLGA NPs and EMF can be an innovative strategy for delivering SQV into the brain.